Dr. Brannan is a neuroscience drug development expert with over 15 years of experience overseeing clinical development and medical affairs. He has held senior roles at Forum Pharmaceuticals, Takeda, Novartis, Cyberonics, Eli Lilly, and most recently served as Chief Medical Officer at Karuna Therapeutics. He has contributed to the development of several important CNS treatments, including Cymbalta®, Exelon Patch®, Trintellix®, and Vagal Nerve Stimulation for Treatment-Resistant Depression. His experience spans drug development, regulatory strategy, launch, and lifecycle management across psychiatry and neurology.

Dr. Robison is a board-certified psychiatrist and clinical researcher specializing in ketamine and psychedelic medicine. He has served as principal investigator on more than 250 CNS clinical trials, including pivotal studies of psilocybin, LSD, 5-MeO-DMT, and MDMA-assisted psychotherapy. His early work with IV ketamine for treatment-resistant depression helped lay the foundation for subsequent large-scale studies and approvals. Dr. Robison is first author of the 2025 JAMA Psychiatry publication on MindMed’s MM120 for generalized anxiety disorder and co-author of Usona’s Phase II psilocybin trial manuscript. He previously founded Cedar Clinical Research—one of the top-enrolling Phase II–III psychedelic trial sites—and Cedar Psychiatry.

Dr. Zoda brings 30 years of leadership in CNS clinical research, with deep expertise across operations, business development, and strategic trial execution. He has held senior roles at PPD, Apex Innovative Sciences, and CenExel, and previously served as EVP and General Manager of the CNS Business Unit at Syneos Health, where he helped lead significant expansion. At CRC, Dr. Zoda guides sponsors through the complexity of trial design and delivery, with a sharp focus on aligning pace with performance. His career has been defined by helping teams navigate high-stakes studies with clarity.